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S umma r y
Background: Anakinra is an interleukin-1 receptor antagonist (IL-1Ra)
that blocks the biological activity of IL-1, including inflammation. Ana -
kinra in combination with methotrexate (MTX) is indicated for reduc-
tion in signs and symptoms in active rheumatoid arthritis, in adults
who have failed one or more disease-modifying antirheumatic
drugs (DMARDs). 
Material and methods: According to the rules of evidence-based 
medicine popularized by The Cochrane Collaboration, a systematic
review of medical literature has been performed in order to assess
clinical efficacy and safety of the therapy. The review yielded three
randomized clinical studies which compared the administration of
anakinra in combination with MTX (or other DMARDs) to placebo with
MTX. 
Results: Moderate clinical efficacy defined as ACR20, ACR50 and ACR70
response and safety profile of anakinra in combination with MTX or
other DMARDs was proven in most studies mentioned and confirmed
by the results of the meta-analysis performed. 
Conclusions: Injection site reactions were the most common adverse
events frequently leading to withdrawal.
S t r e s z c z e n i e
Wstęp: Anakinra jest rekombinowanym ludzkim antagonistą receptora
interleukiny 1 (IL-1Ra), który prowadzi do zahamowania aktywności bio-
logicznej IL-1, m.in. działania prozapalnego. Anakinra w skojarzeniu z meto-
treksatem (MTX) jest zalecana w leczeniu przedmiotowych i podmioto-
wych objawów reumatoidalnego zapalenia stawów (RZS) u dorosłych
pacjentów, u których zastosowanie jednego lub więcej leków modyfi-
kujących przebieg choroby (LMPCh) nie przyniosło pożądanych efektów. 
Materiał i metody: W celu oceny skuteczności klinicznej tej opcji tera-
peutycznej, zgodnie z zasadami medycyny opartej na dowodach nauko-
wych (evidence based medicine – EBM) zalecanymi przez organizację The
Cochrane Collaboration oraz polską Agencję Oceny Technologii Medycz-
nych (AOTM), dokonano systematycznego przeglądu literatury medycz-
nej, w wyniku którego odnaleziono łącznie trzy badania kliniczne z ran-
domizacją dotyczące porównania anakinry stosowanej z MTX (lub
innymi LMPCh) względem placebo podawanego z MTX. 
Wyniki: Umiarkowana skuteczność kliniczna wg kryteriów ACR20,
ACR50, ACR70 i bezpieczeństwo stosowania anakinry w terapii skojarzonej
u pacjentów z RZS została potwierdzona w większości odnalezionych 
badań oraz dodatkowo na podstawie wyników metaanaliz przeprowa-
dzonych z wykorzystaniem wyników przeglądu systematycznego. 
Wnioski: Najczęstszym występującym działaniem niepożądanym, któ-
re w wielu przypadkach było przyczyną rezygnacji z dalszego leczenia,
było pojawienie się reakcji alergicznej w miejscu wstrzyknięcia leku. 
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic disease
of the connective tissue, characterized by inflammation of
the synovial membrane, non-specific inflammation of sym-
metric joints, the presence of extra-articular changes, and
systemic complications, leading to disability, handicap and
premature death [1, 2]. Rheumatoid arthritis has a multi-
factorial aetiopathogenesis [3], but it is believed that initi-
ation of the disease is linked to the activation of T-lympho -
cytes and macrophages, which are responsible for amplifying
and sustaining an abnormal inflammatory response through
the release of pro-inflammatory cytokines [4]. The level of
interleukin-1 (IL-1) in the synovial membrane or serum cor-
relates with disease activity in the respective joints [5]. In
recent years, decreasing the activity of pro-inflammatory
cytokines, including IL-1, has become the goal of new bio-
logical therapies used in the treatment of RA. 
Anakinra, which belongs to the group of biological drugs,
is a recombinant human competitive antagonist of the IL-1
receptor (IL-1Ra), and its administration to patients with RA
results in a positive response to treatment in regard to
reduced prostaglandin E2 release, metalloproteinase pro-
duction (collagenase and stromelysin), and the degree of pro-
teoglycan degradation [6, 7]. 
According to the most recent recommendations regard-
ing clinical practice in Poland, biological drugs, among them
rituximab and abatacept, are used as additional treatment
in patients in whom therapy using traditional disease-mod-
ifying anti-rheumatic drugs (DMARDs) was ineffective [2].
It should be noted that the use of anakinra was not includ-
ed in the 2008 Guidelines on Clinical Practice in Poland [2]
discussed here, nor in the current specifications of the drug
programme outlining administration of biological drugs to
patients with RA and juvenile idiopathic arthritis (JIA), who
failed to respond to treatment with at least two disease-
modifying anti-rheumatic drugs [8]. In accordance with the
2010 EULAR (European League Against Rheumatism) rec-
ommendations [9, 10], anakinra is not recommended for use
in the treatment of patients with RA because of a lack of suf-
ficient data on the drug’s effectiveness. It should be added
that in the age of extended-action biological drugs (adali-
mumab, etanercept, infliximab, and rituximab), administered
at intervals of several weeks or months [8], anakinra,
which must be administered subcutaneously on a daily basis,
is only used sporadically. 
The aim of this study was to provide scientific evidence
for the clinical effectiveness and safety of anakinra used
in combination with methotrexate (MTX) or other disease-
modifying anti-rheumatic drugs for the treatment of RA.
Material and methods
In order to assess the clinical effectiveness of the use
of anakinra in combination with MTX, a systematic review
of medical literature was conducted by searching the 
MEDLINE (PubMed), EMBASE and Cochrane databases for
indexed publications, published up until the 20th of April
2012, regarding anakinra in the treatment of the objective
and subjective symptoms of RA in adults. The review was
conducted in accordance with the standards of scientific
evidence-based medicine (EBM) recommended by The
Cochrane Collaboration [11] and the Polish Agency for Health
Technology Assessment (Agencja Oceny Technologii 
Medycz nych – AOTM) [12]. The search strategy consisted
of the following key words, linked together by logical
Boolean operators: (rheumatoid arthritis OR arthritis de -
formans OR arthrosis deformans OR rheumatic arthritis) –
in regard to population AND (Anakinra OR Kineret OR Antril
OR IL 1 febrile inhibitor OR Interleukin 1 Inhibitor Urine OR
IL-1 Inhibitor Urine OR IL 1 Inhibitor Urine OR IL-1Ra OR
Recombinant interleukin 1 receptor antagonist OR Recom-
binant interleukin 1 receptor blocker) in regard to inter-
ventions. The results were limited to studies involving
human subjects (Humans) and methodological filters
were used to identify randomized clinical trials (Clinical Tri-
als; Randomized Clinical Trials; Controlled Clinical Trials).
The search was designed to identify publications in the fol-
lowing languages: English, Polish, French, and German. All
randomized clinical trials that assessed the effectiveness
and safety of the use of anakinra in combined therapy in
adult patients with RA were included. After excluding all
the publications that did not fulfil the thematic or method-
ological criteria, the search produced a total of 3 randomized
clinical trials that addressed a comparison of anakinra com-
bined with MTX vs. placebo administered with MTX:
Cohen 2002 [13, 14], Cohen 2004 [15], and Bao 2011 [16] as
well as one randomized clinical trial that addressed
a comparison of the safety profile of anakinra, used in com-
bination with disease-modifying drugs (among others,
methotrexate) versus placebo combined with disease-
modifying drugs (among others, methotrexate) – the
2003 Fleischmann study [17, 18]. In addition, the extensive
search of medical databases brought to light another non-
randomized observational study that addressed the use of
anakinra in combination with MTX in patients with RA. 
This review only mentions full-text publications on the
above trials, published in peer-reviewed journals. 
Results
The clinical effectiveness of a wide spectrum of doses
of anakinra combined with MTX was assessed in the ran-
domized 2002 Cohen trial [13, 14] (Table I). Patients (419
patients with RA) were randomly assigned to one of 6 groups,
in which the participants received anakinra in doses rang-
ing from 0.04 mg/kg b.w. to 2.0 mg/kg b.w. or placebo in the
form of subcutaneous injections (Table I). After 12 and 24
weeks of treatment, a statistically significantly larger num-
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ber of patients achieved a response to treatment in accor-
dance with criteria established by the American College of
Rheumatology (ACR) – ACR20, ACR50, and ACR70 – in the
groups treated with anakinra in doses of 1.0 mg/kg b.w. and
2.0 mg/kg b.w. compared to the placebo group. The results
were as follows – after 12 weeks, respectively: ACR20 – 46%
vs. 19% and 38% vs. 19%, ACR50 – 19% vs. 4% and 24% vs.
4%, and ACR70 – 5% vs. 0% and 11% vs. 0%; after 24 weeks,
respectively: ACR20 – 42% vs. 23% and 35% vs. 23%,
ACR50 – 24% vs. 4% and 17% vs. 4%, and ACR70 – 10% vs.
0% and 7% vs. 0%. 
Observations also showed that the groups of patients
receiving anakinra in doses of 1.0 mg/kg b.w. and 2.0 mg/kg
b.w. had a statistically significant sustained response to
treatment (defined as meeting ACR20 improvement criteria
with improvement sustained over a period of at least 4 to
6 months of the study).
Overall, treatment with anakinra was well tolerated by
patients and the most common adverse events were mild
or moderate injection site reactions, whose occurrence was
dose related. However, they were the most common rea-
son for patient withdrawal from the study. Other commonly
observed adverse reactions included headaches, upper res-
piratory tract infections, and mild sinusitis; therefore it was
not necessary to discontinue therapy.
The clinical effectiveness and safety of anakinra at a dose
of 100 mg/day administered together with MTX was con-
firmed in the 24-week randomized, double blinded 2004
Cohen study [15] (Table I). Every 4 weeks patients underwent
evaluation to establish changes in their clinical status and
the presence of adverse events. The primary end point was
ACR20 response after 24 weeks of treatment and the most
important remaining end points were: changes in the indi-
vidual parameters in accordance with ACR criteria, the Health
Assessment Questionnaire (HAQ) score, C-reactive protein
(CRP) concentration, erythrocyte sedimentation rate (ESR)
value, ACR50 and ACR70 responses, and sustained ACR20
response. After 24 weeks of treatment, a statistically sig-
nificant larger number of patients achieved ACR20, ACR50,
and ACR70 improvement in the group treated with anakin-
ra than in the group receiving a placebo (38% vs. 22%, 17%
vs. 8%, and 6% vs. 2%, respectively). The significance of the
results with regard to ACR20 responses was confirmed by
a sensitivity analysis that involved 387 patients who had com-
pleted the study (47% vs. 29%). Statistically significant ACR20
improvement occurred after just 4 weeks of the study, and
observations revealed that a higher percentage of patients
in the study group had sustained improvement compared
to the placebo group (27% vs. 12%). It was also determined
that patients treated with anakinra had an improvement in
all of the components of the ACR response criteria (such as
the number of tender or painful joints, disease activity eval-
uated by the physician and the patient, intensity of pain eval-
uated by patients, CRP concentration, ESR, and HAQ score)
with the exception of the number of swollen joints. It should,
however, be added that at present the most important ther-
apeutic effect associated with the use of biological drugs
should be the achievement of remission or very low disease
activity in a short period of time (3–6 months) [10]; there-
fore the fact that 6% of patients receiving anakinra over 
6 months of treatment achieved an ACR70 response does
not appear to be a satisfactory result. The incidence of adverse
reactions at injection sites was almost 3-fold higher in the
group of patients receiving anakinra than in the placebo group
(65% vs. 24%) and these were often the reason for patient
withdrawal from the study (8.4% vs. 0.8%), although they
were judged to be of mild or moderate intensity. Both ther-
apeutic groups had a similar incidence of other adverse
events, such as infections or serious adverse events. 
The results of the 2004 Cohen study confirmed the mod-
erate clinical effectiveness and safety of anakinra at
a dose of 100 mg/day in combination with MTX and prove
that the designated dose of medication is suitable for use
in actual clinical practice. Among the strengths of the
analysed trial, influencing the credibility of obtained
results, was the good balance achieved among various
potentially disruptive factors between the study arms as
well as inclusion and exclusion criteria corresponding to
the indications for use of the studied therapy. The period
of observation, which amounted to 24 weeks, was a lim-
iting factor; it was too short to permit an evaluation of long-
term effects associated with the use of anakinra.
The next randomized, double-blinded study, conduct-
ed by Bao in 2011 [16], addressed the use of anakinra at
a dose of 80 mg/day combined with MTX (Table I). Every
4 weeks, study participants underwent evaluation to
establish changes in their clinical status and the presence
of adverse events. The primary end point was ACR20
response after 24 weeks of treatment and the most
important remaining end points were: ACR50 and ACR70
response and improvement in DAS28 score values (Euro-
pean League Against Rheumatism Disease Activity Score
28). After 24 weeks of treatment, a statistically significant
larger number of patients receiving anakinra achieved
ACR20 improvement compared with placebo (64% vs. 17%).
Fifteen patients in the anakinra group (36%) failed to
respond to treatment, since they did not achieve an
improvement of at least 20% or else patients withdrew from
the study before its completion. Moreover, the percentage
of patients who met the ACR50 and ACR70 improvement
criteria was higher in the group treated with anakinra than
in the placebo group (38% vs. 0% and 17% vs. 0%, respec-
tively); however, in the case of ACR70, this result was not
statistically significant (α = 0.05). In view of the most recent
EULAR recommendations [10] with regard to the desired
clinical effectiveness of biological therapies, it is difficult
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to consider these results satisfactory. Interestingly, obser-
vations over the 24 weeks of the study revealed that 9 out
of the 42 patients receiving anakinra (21.4%), who initial-
ly responded well to treatment, experienced a secondary
reduction in the effectiveness of the treatment or failure
of the therapy that led to withdrawal. The results revealed
a reduction in DAS28 scores compared to baseline values
in both study groups; however, the difference in the
group treated with anakinra was statistically significant-
ly larger than in the group receiving placebo. 
The results of this study confirm that administration
of anakinra results in improvement in patients with RA after
24 weeks of treatment, assessed according to ACR crite-
ria. Secondary treatment failure in some patients who ini-
tially responded to treatment is a surprising development. 
A multicentre (169 centres in 9 countries), randomized,
double-blinded study conducted in 2003 by Fleischman 
[17, 18] assessed the safety of anakinra therapy at a dose
of 100 mg/day administered over 6 months as adjuvant
therapy to patients with RA treated with DMARDs (Table I).
Patients were characterised by large differences in their RA
activity and concomitant treatment (30% – MTX, 22% – MTX
+ another DMARD, 21% – no DMARDs, 47% – DMARDs +
corticosteroids, and 10.5% – none of the above medications).
The majority of patients complied with their physicians’
recommendations and over 90% of them took at least 90%
of their prescribed drug doses. In the group treated with
anakinra, the incidence of allergic-inflammatory injection
site reactions was significantly higher compared to the
group receiving the placebo (72.6% vs. 32.9%), but the
majority of these were transient reactions of mild or mod-
erate intensity. An increase in RA symptom severity was
observed in 20% of patients who experienced adverse
events in the group treated with anakinra and in 27.6% of
patients in the placebo group (the differences were not sta-
tistically significant). Furthermore, no statistically signif-
icant differences between groups were noted with regard
to the risk of death, serious and severe adverse events, and
withdrawal from treatment as a result of adverse events
and infections. The incidence of serious infections during
the course of anakinra therapy was significantly higher than
with the placebo (2.1% vs. 0.4%). The results of the pre-
sented study confirm that the safety of anakinra admin-
istered to patients with RA is relatively high. The purpose
of including a large number of patients in this study was
to identify potential rare serious adverse events.
A meta-analysis of the results of clinical trials presented
in this review was conducted in order to assess the clin-
ical effectiveness and safety of anakinra after 24 weeks of
treatment. The meta-analyses examined a more diverse
patient population than that of each individual study (with
regard to stages of the disease, patient age, racial group,
and adjuvant medications) as well as a more diverse range
of doses of anakinra. Effectiveness was assessed based on
a meta-analysis for ACR20 response (relative risk), ACR50
and ACR70 response (odds ratio calculated using the Peto
method due to the absence of a particular end point in at
least one of the groups) and produced a statistically sig-
nificant result for each of these end points that confirmed
the moderate effectiveness of anakinra in the examined
dose range (1–2 mg/kg b.w. per day, 80 mg/day, and 100
mg/day) combined with methotrexate in patients with
Fig. 1. ACR70 response – meta-analysis.
Cohen 2002 (1–2 mg/kg/day)
Cohen 2004 (100 mg/day)
Bao 2011 (80 mg/day)
Meta-analysis
4.66 (1.10, 19.78)
2.84 (1.16, 6.94)
4.26 (0.64, 28.28)
3.38 (1.67, 6.84)
ACR70
0.5         1           2                5            10                                           100
Peto odds ratio (95% CI)
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active RA (Fig. 1). The results of the meta-analysis address-
ing the safety of anakinra administered in doses of 1–2
mg/kg b.w. per day and 100 mg/day in combination with
methotrexate or other DMARDs indicate that, compared
to patients who received a placebo, patients receiving
anakinra had a significantly higher incidence of allergic reac-
tions at the site of injection of the drug (injection site reac-
tions – ISR), and of withdrawal from treatment as a result
of such reactions, but there were no differences with regard
to the overall incidence of adverse events or serious adverse
events (Figs. 2 and 3). The results of the meta-analysis indi-
cate that anakinra administered in the above-mentioned
doses does not increase the risk for developing adverse
events (overall), serious adverse events, infections, or seri-
ous infections. 
The results of observational studies confirm the effec-
tiveness of treatment with anakinra in combination with MTX
or other DMARDs in accordance with ACR20 [19, 20], EULAR
[21], and DAS28 criteria [20, 21]. In addition, it was confirmed
that anakinra combined with MTX improves patients’ func-
tional status assessed using the HAQ questionnaire [21], as
well as reducing the number of swollen joints and painful 
joints, the severity of pain and serum C-reactive protein con-
centration [20].
The analysis of the safety of anakinra revealed that the
most common adverse events following its administration
were: allergic reactions at the injection site [20–22], joint pain
[22], a worsening of the symptoms of RA [22], and infections
[21, 22]. Severe infections were extremely rare [20, 22]. The
results obtained in observational studies confirm the con-
clusions drawn from randomized trials.
The results of a study conducted on the basis of an
analysis of registers in Britain for patients who received
anakinra in combination with other DMARDs revealed that
Fig. 3. Serious adverse events – meta-analysis.
Fleischman 2003 (100 mg/day)
Cohen 2004 (100 mg/day)
Meta-analysis
0.99 (0.64, 1.56)
1.26 (0.52, 3.04)
1.04 (0.70, 1.56)
Serious adverse events
0.5                      1                     2                               5
Relative risk (95% CI)
Fig. 2. Overall adverse events – meta-analysis.
Fleischman 2003 (100 mg/day)
Cohen 2004 (100 mg/day)
Meta-analysis
1.00 (0.96, 1.04)
1.11 (1.04, 1.20)
1.05 (0.94, 1.17)
Overall adverse events
0.5                                          1                                            2
Relative risk (95% CI)
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anakinra may increase the risk of developing serious
infections. In view of this, treating physicians should mon-
itor their patients’ condition for such events [23].
Final remarks
Anakinra received marketing authorization for the treat-
ment of adult patients with RA from the American Food and
Drug Administration (FDA) in 2001 and from the European
Medicines Agency (EMA) in 2002. In Poland, anakinra is
available under the brand name of Kineret® and is indicated
for use in combined therapy with MTX to treat the objec-
tive and subjective symptoms of RA in adults who failed
to achieve a satisfactory response to MTX in monothera-
py. The recommended dose of anakinra is 100 mg once dai-
ly in the form of subcutaneous injections. 
The results of this independent review of medical data-
bases and results of meta-analyses confirm the moderate
clinical effectiveness (with regard to the most recent EULAR
guidelines [10]) and the safety of anakinra in the above-
mentioned dose. Adverse effects are generally mild or mod-
erate and serious adverse events (including infections) are
very rare. The risk of serious infections (which included
events that required hospitalization or intravenous admin-
istration of an antibiotic) established by the Fleischman
study [17, 18], a cause for alarm, was also analysed in a paper
by Salliot et al. [24], which reviewed the increased risk of
their occurrence associated with the use of biological drugs.
Similarly to the findings of the current review, a meta-analy-
sis of the results of isolated studies, presented in that paper
[24], did not demonstrate a statistically significant high-
er risk of developing serious infections. Attention was drawn
to the fact that based on the analysed studies [24],
administration of anakinra at a dose of 100 mg/day
results in a significantly higher risk of serious infections than
with lower doses of the drug or a placebo; however, this
risk is closely linked to the presence of co-morbidities [24].
The risk of serious infections associated with administra-
tion of anakinra and other biological drugs used in
patients with RA in combination with DMARDs does not
appear to be high. Nonetheless, it should be kept in mind
by treating physicians [23].
The authors of this paper do not have any obligations
that constitute a conflict of interest. The study was con-
ducted without any financial support. 
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